I agree that this site is using cookies. You can find further informations here.
X
Bruckert, E
336  results:
english X
Search for persons X
?
1

Transcriptomic profile helps to identify high-risk heterozy..:

Pirbay, T. ; Carreau, V. ; Guérin, M....
Archives of Cardiovascular Diseases.  117 (2024)  1 - p. S107-S108 , 2024
Link: https://doi.org/10.1016/..
 
?
2

Towards a readjustment of diagnostic criteria for familial ..:

Bluteau, O. ; Lapidus, N. ; Giral, P....
Archives of Cardiovascular Diseases Supplements.  15 (2023)  1 - p. 108-109 , 2023
Link: https://doi.org/10.1016/..
 
?
3

Treatment of pediatric heterozygous familial hypercholester..:

Peretti, N. ; Vimont, A. ; Mas, E....
Clinical Nutrition ESPEN.  58 (2023)  - p. 568 , 2023
Link: https://doi.org/10.1016/..
 
?
4

Predictive factors of statin initiation during childhood in..:

Peretti, N. ; Vimont, A. ; Mas, E....
Atherosclerosis.  355 (2022)  - p. 11 , 2022
Link: https://doi.org/10.1016/..
 
?
5

EPH37 High Cardiovascular Disease Risk and Low Lipid-Loweri..:

Ferrières, J ; Farnier, M ; Bruckert, E..
Value in Health.  25 (2022)  12 - p. S198 , 2022
Link: https://doi.org/10.1016/..
 
?
6

Non-calcific atherosclerotic burden in HeFH: The FH-CALC st..:

Gallo, A. ; Carreau, V. ; Mondelli, A....
Atherosclerosis.  355 (2022)  - p. 30 , 2022
Link: https://doi.org/10.1016/..
 
?
7

Final results from the pan-European observational heymans s..:

Ray, K.K. ; Bruckert, E. ; Perrone-Filardi, P....
Atherosclerosis.  355 (2022)  - p. 14 , 2022
Link: https://doi.org/10.1016/..
 
?
8

Effects of patient characteristics on volanesorsen efficacy..:

Witztum, J.L. ; Gaudet, D. ; Freedman, S....
Atherosclerosis.  355 (2022)  - p. 215 , 2022
Link: https://doi.org/10.1016/..
 
?
9

Enrichment of high-density lipoproteins with phosphatidylet..:

Taradeh, M. ; Dahik, V. ; Lhomme, M....
Atherosclerosis.  355 (2022)  - p. 72 , 2022
Link: https://doi.org/10.1016/..
 
?
10

Rationale and design of two trials assessing efficacy, safe..:

Reijman, M.D. ; Schweizer, A. ; Peterson, A.L.H....
Atherosclerosis.  355 (2022)  - p. 150 , 2022
Link: https://doi.org/10.1016/..
 
?
11

Extreme lipoprotein(a) levels and sub-clinical atherosclero..:

Perregaux, J.-F. ; Bruckert, E. ; Gallo, A.
Atherosclerosis.  355 (2022)  - p. 60-61 , 2022
Link: https://doi.org/10.1016/..
 
?
12

Potential cardiovascular risk reduction with evolocumab in ..:

Ray, K ; Bridges, I ; Bruckert, E...
European Heart Journal.  42 (2021)  Supplement_1 - p. , 2021
Link: https://doi.org/10.1093/..
 
?
13

Non-alcoholic fatty liver disease and subclinical atheroscl..:

Mondelli, A. ; Redheuil, A. ; Giral, P....
Atherosclerosis.  331 (2021)  - p. e202-e203 , 2021
Link: https://doi.org/10.1016/..
 
?
14

Evolocumab use and LDL-C lowering in a cohort of european p..:

Sibartie, M. ; Dhalwani, N. ; Bridges, I....
Atherosclerosis.  331 (2021)  - p. e253 , 2021
Link: https://doi.org/10.1016/..
 
?
15

Evolocumab use and LDL-C lowering in a cohort of European p..:

Sibartie, M. ; Dhalwani, N. ; Ebenbichler, C...
Atherosclerosis.  331 (2021)  - p. e21 , 2021
Link: https://doi.org/10.1016/..
 
1-15